Article Text

Download PDFPDF
Liver disease progression and virological response: entecavir rescue still possible in the setting of rtM204I lamivudine-resistant mutation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors PST: acquisition of data, analysis and interpretation of data, drafting and finalising the manuscript. MOA: acquisition of data, analysis of data. YYD, YML, KL, HCL, GHL, MAT, CS: acquisition of data. SGL: study concept and design, study supervision, analysis and interpretation of data, critical revision of draft of manuscript, approval of final version of manuscript.

  • Funding The study was funded by a National University Hospital Research Grant, grant number: NBDT05DMED02 Gastro Fund. This funder was our hospital. It provided the funding as well as the facilities for this investigator-initiated study.

  • Competing interests Seng Gee Lim is on the Advisory Board of Novartis, Gilead Sciences, Merck Sharp and Dohme, Janssen, Archillion and Bristol Myers Squibb, and is on the speaker's Bureau for GlaxoSmithKline, Merck Sharpe and Dohme, and Bristol Myers Squibb. None of the other coauthors have any disclosures to declare.

  • Ethics approval This study was approved by the National Healthcare Group Institutional Review Board, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Linked Articles